The FDA office of Women's Health and Center for Drug Evaluation and Research and hosting a public workshop with a focus on testosterone use in menopausal women.
News|Articles|September 21, 2026
Contemporary OB/GYN Weekly Review: Testosterone evidence, ECV counseling, and more
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Benjamin P. Saylor
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
Advertisement
Advertisement
Thank you for visiting the Contemporary OB/GYN website. Take a look at some of our top stories from the past week (Monday, September 14, to Friday, September 18, 2026) and click on each link to read and watch anything you may have missed.
Related to this article
Take a look back at some of the top FDA and pipeline news in women's health from August 2026.
A new Gallup survey found 51% of women in the United States reported negative healthcare experiences.
A new study links earlier menopause age to faster cognitive decline and earlier Alzheimer diagnosis.
Bruce Dorr, MD, FACOG, URPS, FMCP-M, weighs his own experience with pellet therapy against guideline evidence, then he and Maria Uloko, MD, close with candid advice for clinicians too afraid of hormones to start prescribing.
Bruce Dorr, MD, FACOG, URPS, FMCP-M, and Maria Uloko, MD, walk through real-world dosing, cost workarounds, and the labs that actually matter for safety and efficacy.
Bruce Dorr, MD, FACOG, URPS, FMCP-M, and Maria Uloko, MD, reframe testosterone candidacy around clinical presentation and hormone state, not age cutoffs or a single number on a chart.
Before prescribing testosterone, know what the evidence actually proves. Maria Uloko, MD, draws a sharp line between the one population the data supports and the much wider group of women asking about it.
Advertisement
Advertisement